HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

Files in This Item:
BreastCancer24_473.pdf257.03 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/70047

Title: Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
Authors: Ogiya, Akiko Browse this author
Yamazaki, Kieko Browse this author
Horii, Rie Browse this author →KAKEN DB
Shien, Tadahiko Browse this author →KAKEN DB
Horimoto, Yoshiya Browse this author
Masuda, Norikazu Browse this author
Inao, Touko Browse this author
Hosoda, Mitsuchika Browse this author →KAKEN DB
Ishida, Naoko Browse this author
Osako, Tomofumi Browse this author
Takahashi, Masato Browse this author
Endo, Yumi Browse this author →KAKEN DB
Miyoshi, Yuichiro Browse this author
Yasojima, Hiroyuki Browse this author
Tomioka, Nobumoto Browse this author
Yamashita, Hiroko Browse this author →KAKEN DB
Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society Browse this author
Keywords: Breast cancer
Post-relapse survival
Prognosis
Estrogen receptor-positive
Endocrine therapy
Issue Date: May-2017
Publisher: Springer
Journal Title: Breast cancer
Volume: 24
Issue: 3
Start Page: 473
End Page: 482
Publisher DOI: 10.1007/s12282-016-0730-3
PMID: 27628678
Abstract: Background: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. Methods: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed. Results: Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy >6 months than in those with a duration ≤6 months. Conclusion: Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.
Rights: The final publication is available at link.springer.com
Type: article (author version)
URI: http://hdl.handle.net/2115/70047
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 山下 啓子

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University